Nearly 8,000 bottles of a widely prescribed blood pressure medication have been pulled from the market under a Class II recall after the drug's manufacturer discovered that an incorrect expiration date was printed on the packaging. The U.S. Food and Drug Administration updated its enforcement reporting on July 17, 2026, with details on the recall, which was originally initiated on July 2, 2025, by Lupin Pharmaceuticals, Inc., based in Naples, Florida.
The recall covers 7,668 bottles of prescription Amlodipine and Benazepril HCl Capsules USP, 2.5 mg/10 mg, in 100-count bottles, lot number GB01616. The labeling error: the affected bottles show an expiration date of February 28, 2027, when the correct expiration date is January 2027, a one-month discrepancy that the FDA has classified as a potential source of harm if patients use medication they believe to be within its effective window when it has actually expired.
Why This Matters
High blood pressure, or hypertension, affects nearly half of all American adults, according to the CDC. Amlodipine and benazepril is a combination medication commonly used to control blood pressure in patients whose disease is not adequately managed by a single drug. It is a generic equivalent of the brand-name drug Lotrel, previously marketed by Novartis. For patients taking this medication daily, any uncertainty about whether their supply is still effective is a medical concern, not just a paperwork issue.
Expiration dates on medications exist for a specific reason: drug potency can degrade after manufacture due to temperature changes, humidity, and the passage of time. A mislabeled expiration date means that a patient checking whether their medication is still good cannot rely on the date printed on their bottle. The FDA states clearly: "Once the expiration date has passed, there is no guarantee that the medicine will be safe and effective," according to reporting from The Healthy.
For a patient managing hypertension who unknowingly takes expired medication that has lost potency, blood pressure may not be adequately controlled, increasing the short-term risk of cardiovascular events including heart attack and stroke.
What We Know So Far
The recall was first initiated by Lupin Pharmaceuticals on July 2, 2025, and is classified by the FDA as a Class II recall, meaning the agency has determined that use of the product may cause temporary or medically reversible adverse health consequences, or that the probability of serious adverse health consequences is remote. The affected bottles were distributed nationwide throughout the United States.
The specific mislabeling error, as described in the FDA enforcement report, is as follows: lot GB01616 was released with an expiration date of February 2027, when the correct expiration date is January 2027. The product is manufactured by Lupin Limited in Goa, India, for Lupin Pharmaceuticals, Inc. in the United States.
Recall number D-0542-2025 identifies this enforcement action in the FDA's tracking system. As of the FDA's July 17, 2026, update, the recall is listed as ongoing.
Where the Risk Is Highest
Because the recall affected distribution throughout the United States, there is no specific geographic concentration of risk. Patients in every state may have received this lot. The key variable is whether patients received lot GB01616 from their pharmacy, which is determined by the lot number printed on the bottle rather than by location.
Patients who use independent or local pharmacies, where inventory turnover may be slower than at large chain pharmacies, and those who purchase 90-day supplies of maintenance medications are most likely to still have recalled bottles in their possession, particularly since the recall was initiated in July 2025 and some bottles with extended expiration dates may still be in household medicine cabinets.
What Doctors and Experts Say
The FDA's classification of this recall as Class II reflects the agency's assessment that the primary risk is related to medication potency after expiration, not to a chemical contamination or manufacturing defect that would make the drug acutely dangerous. The harm pathway is indirect: a patient who believes their medication is within its expiration date and continues taking it after January 2027, not realizing the correct expiration has passed, may be taking less potent medication without knowing it.
Pharmacists who have dispensed the recalled lot number are required by FDA recall procedures to notify patients. However, because the recall was initiated in 2025, some patients may not have received notification. The FDA strongly encourages patients to verify their lot number against the recall list independently, as reported by Yahoo News in its coverage of the July 2026 FDA enforcement update.
What the Evidence Shows and What It Does Not
A labeling error with a one-month expiration date discrepancy is among the less severe categories of pharmaceutical recall. The drug itself is not contaminated, structurally compromised, or manufactured to an incorrect formulation. The core issue is that patients cannot rely on the date printed on the label to determine when their medication actually expires.
This is distinguished from recalls involving chemical contamination such as nitrosamine impurities, which have driven numerous blood pressure medication recalls in prior years involving valsartan, losartan, and other angiotensin receptor blockers. This recall carries no contamination or impurity concern.
However, for a medication taken daily to control a chronic condition, any reduction in potency that occurs after actual expiration and goes unrecognized by the patient represents a genuine risk. Blood pressure medications that lose effectiveness may allow hypertension to go uncontrolled without the patient realizing it, since hypertension is typically asymptomatic until a cardiovascular event occurs.
Who Faces the Greatest Risk
Patients who filled a 90-day prescription of Amlodipine and Benazepril HCl Capsules USP 2.5 mg/10 mg and received lot GB01616 are the directly affected population. Older adults who manage multiple chronic conditions, who may have reduced capacity to independently navigate a pharmaceutical recall notice, and who may be more sensitive to uncontrolled blood pressure fluctuations, are at higher risk of harm if they continue taking expired medication without awareness.
Patients whose blood pressure has been well-controlled on this medication and who do not have it rechecked regularly are less likely to notice if control degrades due to reduced drug potency after expiration.
Symptoms and Warning Signs to Watch For
Hypertension is frequently called the silent killer because it produces no reliable symptoms in most people, even at dangerous levels. However, very high blood pressure can sometimes cause severe headache, particularly at the back of the head, visual disturbances, chest pain, shortness of breath, difficulty breathing, irregular heartbeat, or nosebleeds. These symptoms in a person with known hypertension, particularly if blood pressure has not been recently checked, warrant immediate medical evaluation.
Any patient who suspects their blood pressure may be poorly controlled, whether because of this recall or any other reason, should check their blood pressure at a pharmacy, doctor's office, or using a validated home blood pressure monitor, and share any concerning readings with their health care provider promptly.
What You Can Do Now
Check your blood pressure medication immediately. If you take a prescription combination of amlodipine and benazepril in 2.5 mg/10 mg capsules and the bottle shows a lot number of GB01616, your medication is subject to this recall. Contact your pharmacist or prescribing physician to arrange a replacement prescription.
Do not stop taking your blood pressure medication without speaking with a health care provider first. Even if your current supply may be subject to this recall, abruptly discontinuing blood pressure treatment can cause rebound hypertension and is more dangerous than continuing the medication while arranging a replacement. Contact your pharmacy for a no-cost replacement of the recalled lot.
You can verify recall status and lot information on the FDA Drug Recalls page. Patients can also call Lupin Pharmaceuticals' customer service directly for confirmation. If you believe you have experienced any health effects related to this medication, report it to the FDA through the MedWatch Safety Reporting Portal.
Cost and Access: What Patients Should Know
Patients whose lot is affected are entitled to a free replacement from their pharmacy. Most pharmacies will replace a recalled medication at no cost when a valid recall is in effect. Patients without insurance who rely on generic medications can request the pharmacist to verify whether a non-recalled lot is available and fill or transfer the prescription without additional cost. If a patient has difficulty obtaining a replacement, their state's Board of Pharmacy or a patient advocacy organization can assist.
Amlodipine and benazepril are generic drugs available at relatively low cost at most retail pharmacies. The retail price without insurance for a 30-day supply typically ranges from $20 to $50, depending on the pharmacy and geographic location.
What Happens Next
The FDA will close this recall once all recalled product has been removed from distribution and returned to the manufacturer. Updates to the recall status will be posted to the FDA Drug Recalls page. Patients who receive a recalled lot replacement should dispose of the original recalled bottle by following FDA medication disposal guidelines, which typically recommend mixing with an undesirable substance such as coffee grounds and sealing before discarding, or using a local pharmacy take-back program.
MedicalDaily will follow any updates to this recall's status.
The Bottom Line
This recall affects nearly 8,000 bottles of a combination blood pressure medication due to a one-month expiration date printing error. The risk is indirect but real: patients who unknowingly use expired medication may experience reduced blood pressure control without realizing it. The fix is straightforward. Check your lot number, and if it matches GB01616, contact your pharmacy for a free replacement. Do not stop your medication before arranging a replacement.
